Anand Jha
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Anand Jha has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Bor-Sheng Ko
Division of Hematology Department of Internal Medicine National Taiwan University Hospital Taipei Taiwan
1 shared publication - Diana MacDonell
Pharmaceutical Benefits Advisory, Bedford Park, Australia
1 shared publication - Dong-Churl Suh
College of Pharmacy, Chung-Ang University, Seoul 06974, Korea
1 shared publication - Durhane Wong-Rieger
Canadian Organization for Rare Disorders, Toronto, ON, Canada.
1 shared publication - Ekaphop Sirachainan
Department of Medicine, Ramathibodi Hospital, 34/1 Soi Saengsuksa School, Isarapap Road, Min Buri, 10510 Bangkok, Thailand
1 shared publication - Gilberto Lopes
Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL 33136, USA
1 shared publication
Latest Publications
- Open Access
- 16 September 2014
- Published by Springer Nature in Orphanet Journal of Rare Diseases
- Vol. 9 (1) , 137
A call for action to improve access to care and treatment for patients with rare diseases in the Asia-Pacific region
This article is a call for action to the relevant stakeholders to improve access to care and treatment for patients with rare diseases in the Asia-Pacific region by looking into three main areas: (a) developing legislative definitions to confer enforceable protection, (b) creating or strengthening policies by objectively measuring the impact brought about by rare diseases and establishing platforms to reach out to the rare disease community, and (c) fostering collaboration across sectors and countries. It is hoped that these suggested actions can catalyze discussions and progress in the region.
- 16 September 2014
- Published by Springer Nature in Orphanet Journal of Rare Diseases
- Vol. 9 (1) , 137
Open AccessA call for action to improve access to care and treatment for patients with rare diseases in the Asia-Pacific region
This article is a call for action to the relevant stakeholders to improve access to care and treatment for patients with rare diseases in the Asia-Pacific region by looking into three main areas: (a) developing legislative definitions to confer enforceable protection, (b) creating or strengthening policies by objectively measuring the impact brought about by rare diseases and establishing platforms to reach out to the rare disease community, and (c) fostering collaboration across sectors and countries. It is hoped that these suggested actions can catalyze discussions and progress in the region.